These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 9024247

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cabergoline in the treatment of acromegaly: a study in 64 patients.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
    [Abstract] [Full Text] [Related]

  • 4. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995 Feb; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 6. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 7. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R, Attanasio R, Lodrini S, Lasio G.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [Abstract] [Full Text] [Related]

  • 8. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
    Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A.
    Pituitary; 1999 Jun; 1(2):115-20. PubMed ID: 11081189
    [Abstract] [Full Text] [Related]

  • 10. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 11. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
    Suda K, Inoshita N, Iguchi G, Fukuoka H, Takahashi M, Nishizawa H, Yamamoto M, Yamada S, Takahashi Y.
    Endocr J; 2013 Nov; 60(4):507-15. PubMed ID: 23291436
    [Abstract] [Full Text] [Related]

  • 13. Cabergoline treatment of acromegaly: a preliminary dose finding study.
    Jackson SN, Fowler J, Howlett TA.
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
    [Abstract] [Full Text] [Related]

  • 14. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 15. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 16. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan 12; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 17. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr 12; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 18. CV 205-502 in acromegaly.
    Chiodini PG, Attanasio R, Cozzi R, Dallabonzana D, Oppizzi G, Orlandi P, Strada S, Liuzzi A.
    Acta Endocrinol (Copenh); 1993 May 12; 128(5):389-93. PubMed ID: 8100375
    [Abstract] [Full Text] [Related]

  • 19. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P, Alves Martins MR, Abucham J.
    Neuroendocrinology; 2010 May 12; 92(2):120-7. PubMed ID: 20802256
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2001 Jun 12; 86(6):2779-86. PubMed ID: 11397887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.